Trichostatin A reverses epithelial‑mesenchymal transition and attenuates invasion and migration in MCF‑7 breast cancer cells

Wang,Xiaoxiong; Chen,Shirong; Shen,Taipeng; Lu,Hao; Xiao,Dingqiong; Zhao,Meng; Yao,Yutang; Li,Xiuli; Zhang,Ge; Zhou,Xing; Jiang,Xiao; Cheng,Zhuzhong

doi:10.3892/etm.2020.8422

Trichostatin A reverses epithelial‑mesenchymal transition and attenuates invasion and migration in MCF‑7 breast cancer cells

Authors:
- Xiaoxiong Wang
- Shirong Chen
- Taipeng Shen
- Hao Lu
- Dingqiong Xiao
- Meng Zhao
- Yutang Yao
- Xiuli Li
- Ge Zhang
- Xing Zhou
- Xiao Jiang
- Zhuzhong Cheng
View Affiliations

Affiliations: Positron Emission Tomography/Computed Tomography Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China
Published online on: January 3, 2020 https://doi.org/10.3892/etm.2020.8422
Pages: 1687-1694
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer remains one of the leading causes of mortality in women, and epithelial‑mesenchymal transition (EMT) serves an indispensable role in the invasion and migration of breast cancer cells. As a representative of classical histone deacetylase inhibitors (HDACIs), trichostatin A (TSA) has been demonstrated to reverse EMT in certain types of non‑tumor cells and tumor cells. In the present study, the invasive and migratory abilities of MCF‑7 cells were examined following treatment with TSA. TSA‑induced changes in the expression of an epithelial biomarker epithelial cadherin (E‑cadherin), a mesenchymal biomarker (vimentin), and a transcription factor [zinc finger protein SNAI2 (SLUG)] were also investigated. Transwell invasion and migration assays, and wound healing assays, revealed that the invasive and migratory abilities of MCF‑7 cells were suppressed significantly upon treatment with TSA. Treatment with TSA led to an increased expression level of E‑cadherin, and decreased expression of vimentin and, in MCF‑7 cells. The overexpression of SLUG decreased the expression level of E‑cadherin, but increased vimentin expression, and upon treatment with TSA, these effects were reversed. Additionally, SLUG knockdown also led to upregulation of E‑cadherin expression, downregulation of vimentin expression, and suppression of the invasion and migration of MCF‑7 cells. Taken together, these results suggest that TSA is able to reverse EMT via suppressing SLUG and attenuate the invasion and migration of MCF‑7 cells in vitro, thereby providing a potential avenue for chemotherapeutic intervention in the treatment of breast cancer.

View Figures

View References

1	Lee YT: Breast carcinoma: Pattern of metastasis at autopsy. J Surg Oncol. 23:175–180. 2010. View Article : Google Scholar
2	Weil RJ, Palmieri DC, Bronder JL, Stark AM and Steeg PS: Breast cancer metastasis to the central nervous system. Am J Pathol. 167:913–920. 2005. View Article : Google Scholar : PubMed/NCBI
3	Vaidya JS, Keshtgar M and Baum M: Diseases of the breast. Br J Cancer. 83:1769–1770. 2000. View Article : Google Scholar
4	Behrens J, Mareel MM, Van Roy FM and Birchmeier W: Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 108:2435–2447. 1989. View Article : Google Scholar : PubMed/NCBI
5	Chengsen X, David P, Christo V, Carol X and Neilson EG: The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 63:3386–3394. 2003.PubMed/NCBI
6	Thompson EW, Newgreen DF and David T: Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2005. View Article : Google Scholar : PubMed/NCBI
7	Felipe Lima J, Nofech-Mozes S, Bayani J and Bartlett JM: EMT in breast carcinoma-a review. J Clin Med. 5(pii): E652016. View Article : Google Scholar : PubMed/NCBI
8	Jean Paul T and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
9	Michael Z and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
10	Liu F, Gu LN, Shan BE, Geng CZ and Sang MX: Biomarkers for EMT and MET in breast cancer: An update. Oncol Lett. 12:4869–4876. 2016. View Article : Google Scholar : PubMed/NCBI
11	David S, Socorro María RP, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989–997. 2008. View Article : Google Scholar : PubMed/NCBI
12	Yi P, Jing L, Zhang Y, Wang N, Liang H, Liu Y, Zhang CY, Zen K and Gu H: SLUG-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci Rep. 6:257982016. View Article : Google Scholar : PubMed/NCBI
13	Hajra KM, Chen DY and Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62:1613–1618. 2002.PubMed/NCBI
14	Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J: Vimentin regulates EMT induction by SLUG and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
15	Xu S, Ren J, Chen HB, Wang Y, Liu Q, Zhang R, Jiang SW and Li J: Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells. Curr Pharm Des. 20:1881–1887. 2014. View Article : Google Scholar : PubMed/NCBI
16	Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC and Jiang SW: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther. 5:2767–2776. 2006. View Article : Google Scholar : PubMed/NCBI
17	Yoshikawa M, Hishikawa KT and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007. View Article : Google Scholar : PubMed/NCBI
18	Xiao W, Chen X, Liu X, Luo L, Ye S and Liu Y: Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J Cell Mol Med. 18:646–655. 2014. View Article : Google Scholar : PubMed/NCBI
19	Aki K, Potter JJ, Michael C, Zhen D, Esteban M and Koteish AA: Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology. 52:1033–1045. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Xu J, Wang H, Wu L, Yuan W, Du J and Cai S: Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun. 456:320–326. 2015. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hao W, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, Zhang G, Bu XZ, Cai SH and Du J: Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One. 8:e566642013. View Article : Google Scholar : PubMed/NCBI
23	Gilles C, Newgreen DF, Sato H and Thompson EW: Matrix metalloproteases and epithelial-to-mesenchymal transition. 2005. View Article : Google Scholar
24	Faghihloo E, Akbari A, Adjaminezhad-Fard F and Mokhtari-Azad T: Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines. Iran J Basic Med Sci. 19:601–607. 2016.PubMed/NCBI
25	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
26	Grzegrzolka J, Biala M, Wojtyra P, Kobierzycki C, Olbromski M, Gomulkiewicz A, Piotrowska A, Rys J, Podhorska-Okolow M and Dziegiel P: Expression of EMT Markers SLUG and TWIST in breast cancer. Anticancer Res. 35:3961–3968. 2015.PubMed/NCBI
27	Shih JY and Yang PC: The EMT regulator SLUG and lung carcinogenesis. Carcinogenesis. 32:1299–1304. 2011. View Article : Google Scholar : PubMed/NCBI
28	Jing Y, Cui D, Guo W, Jiang J, Jiang B, Lu Y, Zhao W, Wang X, Jiang Q, Han B and Xia S: Activated androgen receptor promotes bladder cancer metastasis via SLUG mediated epithelial-mesenchymal transition. Cancer Lett. 348:135–145. 2014. View Article : Google Scholar : PubMed/NCBI
29	Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z and You T: HMGA2 induces transcription factor SLUG expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett. 355:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
30	Liu YN, Abou-Kheir W, Yin JJ, Fang L, Hynes P, Casey O, Hu D, Wan Y, Seng V, Sheppard-Tillman H, et al: Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol. 32:941–953. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wang W, Li X, Zhang W, Li W, Yi M, Yang J, Zeng Z, Colvin Wanshura LE, McCarthy JB, Fan S, et al: Oxidored-nitro domain containing protein 1 (NOR1) expression suppresses SLUG/vimentin but not snail in nasopharyngeal carcinoma: Inhibition of EMT in vitro and in vivo in mice. Cancer Lett. 348:109–118. 2014. View Article : Google Scholar : PubMed/NCBI
32	Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan X, Shu G and Song J: Histone deacetylase 1 is required for transforming growth factor-β1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol. 42:1489–1497. 2010. View Article : Google Scholar : PubMed/NCBI
33	Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H and Lee HB: Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-β1-induced renal injury. Am J Physiol Renal Physiol. 297:F729–F739. 2009. View Article : Google Scholar : PubMed/NCBI
34	Xiao W, Chen X, Liu X, Luo L, Ye S and Liu Y: Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J Cell Mol Med. 18:646–655. 2014. View Article : Google Scholar : PubMed/NCBI
35	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
36	Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A and Disis ML: Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 177:1526–1533. 2006. View Article : Google Scholar : PubMed/NCBI
37	Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
38	Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, et al: Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 14:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
39	Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H and Moustakas A: Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene. 27:1218–1230. 2008. View Article : Google Scholar : PubMed/NCBI
40	Yongqing L, Shahenda EN, Darling DS, Yujiro H and Dean DC: Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development. 135:579–588. 2008. View Article : Google Scholar : PubMed/NCBI
41	Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
42	Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
43	Cheng GZ, Joseph C, Qi W, Weizhou Z, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion and resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
44	Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and Slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 27:2059–2068. 2010. View Article : Google Scholar
45	Yang H, Zhang G, Che X and Yu S: Slug inhibition increases radiosensitivity of nasopharyngeal carcinoma cell line C666-1. Exp Ther Med. 15:3477–3482. 2018.PubMed/NCBI